Pfizer
Last updated Jun 27, 2026
Evidence Sources
13
Competitive Findings
8
Portfolio Developments
40
Regulatory Precedents
8
Clinical Programs
8
Confidence Coverage
68%
Audit
- Competitor findings: 8
- Portfolio developments: 40
- Self-competition findings removed: 104
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- mTOR Inhibitor
- Lung Cancer
- Diabetes
- GLP-1
Highest priority development: FDA Approves PHESGO Supplement for Genentech's Combination Therapy
Portfolio development
FDA Approves PHESGO Supplement for Genentech's Combination Therapy is an owned Pfizer portfolio development in Oncology · HER2-positive Breast Cancer.
Competitive pressure: Moderate
Portfolio impact: High
Evidence coverage: 68%
Active Signals
134
Investigate Priority
12
Opportunity Score
60289
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 27, 2026Score 457FDA Approves Supplemental Application for IBRANCE (Palbociclib)
Oncology · CDK4/6 Inhibitor
- MonitorJun 24, 2026Score 456Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
Oncology · Non-small Cell Lung Cancer
- MonitorJun 22, 2026Score 456FDA approves capivasertib with abiraterone for PTEN-deficient prostate cancer
Oncology · Prostate Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)PfizerFDAPortfolio
- Low Confidence · 0%Sources (3)FDAFDAPortfolio
- Low Confidence · 0%Sources (3)Humanexa SignalsFDAPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With InhibitorsHigh Confidence · 95%
Potential competitive pressure
Sources (2)PfizerCompetitiva - European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With InhibitorsHigh Confidence · 95%
Potential competitive pressure
Sources (2)PfizerCompetitiva - TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate CancerModerate Confidence · 67%
Potential competitive pressure
Sources (2)PfizerCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Verified Clinical Benefit | Cancer Accelerated ApprovalsModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Oncology (Cancer)/Hematologic Malignancies Approval NotificationsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Ongoing | Cancer Accelerated ApprovalsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — INQOVI (SUPPL)Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With InhibitorsModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With InhibitorsModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate CancerModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 456Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients
Oncology · Multiple Myeloma
- InvestigateScore 456Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC
- InvestigateScore 456Pfizer's 25vPnC Vaccine Shows Strong Phase 2 Results, Advancing to Phase 3
Infectious Disease · Pneumococcal Vaccine
- EscalateScore 454Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Pfizer right now?
- Which regulatory precedents should Pfizer monitor in Oncology and mTOR Inhibitor?
- How does European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults… compare to the nearest competitive programs?
- What signals require immediate investigation for Pfizer?
- Summarize the strategic implications of recent developments for Pfizer.
- Where is the greatest uncertainty in Pfizer's competitive positioning?